|
|
|
|
|
|
by amluto
722 days ago
|
|
|
I’d like to see a payment structure more like a bounty for efficacy. If you think you can cure DMD, you know up-front what you’ll get paid, and it depends on how well it works, dosing schedule, side effects, etc. If your drug is safe but barely works, you get paid a tiny bit of money. If DMD patients’ families want the drug and the manufacturer is willing to sell it at the appropriately low price, fine. IMO the actual failure here is the fact that Sarepta can charge $3.2M for a product without demonstrated efficacy. |
|
|